Resmetirom
Clinical data
Other namesMGL-3196
Legal status
Legal status
  • Investigational
Identifiers
  • 2-[3,5-dichloro-4-[(6-oxo-5-propan-2-yl-1H-pyridazin-3-yl)oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile
CAS Number
PubChem CID
DrugBank
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC17H12Cl2N6O4
Molar mass435.22 g·mol−1
3D model (JSmol)
  • CC(C)C1=CC(=NNC1=O)OC2=C(C=C(C=C2Cl)N3C(=O)NC(=O)C(=N3)C#N)Cl
  • InChI=1S/C17H12Cl2N6O4/c1-7(2)9-5-13(22-23-15(9)26)29-14-10(18)3-8(4-11(14)19)25-17(28)21-16(27)12(6-20)24-25/h3-5,7H,1-2H3,(H,23,26)(H,21,27,28)
  • Key:FDBYIYFVSAHJLY-UHFFFAOYSA-N

Resmetirom is an experimental drug for the treatment of non-alcoholic steatohepatitis (NASH).[1][2] It is a selective agonist of thyroid hormone receptor-β which increases hepatic fat metabolism and reduces lipotoxicity.[1]

As of 2023, it is in Phase III clinical trials.[3][4]

References

  1. ^ a b Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, et al. (November 2019). "Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial". Lancet. 394 (10213): 2012–2024. doi:10.1016/S0140-6736(19)32517-6. PMID 31727409. S2CID 207976212.
  2. ^ "Non-Alcoholic Fatty Liver Disease (NAFLD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape". Yahoo! Finance. January 23, 2023.
  3. ^ Harrison SA. "A 52-Week Phase 3 Clinical Trial of Resmetirom in 180 Patients with Well-Compensated NASH Cirrhosis". AASLD: The Liver Meeting.
  4. ^ "Madrigal Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis" (Press release). Madrigal Pharmaceuticals. December 19, 2022.
Categories